Former FDA chief backs acting commissioner Diamantas
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Wall Street Journal reports that biotech investors now rank political risk below interest rates, clinical data, and earnings, reflecting reduced concern over the “Make America Healthy Again” movement and criticism from Robert F. Kennedy Jr.
- FDA leadership turnover, including the removal of skeptical officials, has helped calm investor sentiment toward drug companies.
- David Kessler, former FDA commissioner (1990‑1997), told STAT’s Breakthrough Summit West he has “great confidence” in acting commissioner Kyle Diamantas to stabilize the agency and understands the FDA process.
- Kyle Diamantas, the FDA’s acting commissioner, is an attorney rather than a medical doctor, a departure from the usual background of FDA heads.
Why it matters: Biotech investors gain confidence as political risk falls below interest rates, clinical data, and earnings, while the FDA benefits from a steadier leadership environment in the near term.
Ask SkimNews
